Showing results (1-10 of 151) with videos related to

Sort By:
Pageof 16
Primary Care Diabetes|May 23, 2012
Incretin therapy and its effect on body weight in patients with diabetesMarcus Lind
Case Reports in Dermatology|November 25, 2010
Cure of Psoriasis and Arthritis when Addison's Disease Was DetectedMarcus Lind
Frontiers in Clinical Diabetes and Healthcare|November 3, 2023
Evaluating a systematic intensive therapy using continuous glucose monitoring and intermittent scanning glucose monitoring in clinical diabetes care: a protocol for a multi-center randomized clinical trialArndís F Ólafsdóttir, Marcus Lind
Thrombosis Journal|March 6, 2014
Incidence of venous thromboembolism in northern Sweden (VEINS): a population-based studyMagdalena Johansson, Lars Johansson, Marcus Lind
BMJ Open Diabetes Research & Care|June 4, 2024
Prevalence and risk factors for diabetic retinopathy at diagnosis of type 2 diabetes: an observational study of 77 681 patients from the Swedish National Diabetes RegistrySheyda Sofizadeh, Katarina Eeg-Olofsson, Marcus Lind
The British Journal of Clinical Psychology|May 12, 2012
Don't worry, be constructive: a randomized controlled feasibility study comparing behaviour therapy singly and combined with constructive worry for insomniaMarkus Jansson-Fröjmark, Marcus Lind, Rikard Sunnhed
Frontiers in Nutrition|March 30, 2023
Design of a randomized cross-over study evaluating effects of carbohydrate intake on glycemic control in persons with type 1 diabetesSofia Sterner Isaksson, Arndís F Ólafsdóttir, Marcus Lind
Primary Care Diabetes|November 8, 2011
The relationship between the exposure time of insulin glargine and risk of breast and prostate cancer: an observational study of the time-dependent effects of antidiabetic treatments in patients with diabetesMarcus Lind, Martin Fahlén, Björn Eliasson, et al.
European Journal of Preventive Cardiology|February 8, 2019
Physical activity and risk of first-time venous thromboembolismMagdalena Johansson, Lars Johansson, Patrik Wennberg, et al.
Primary Care Diabetes|October 22, 2011
Glucagon-like peptide 1 (GLP-1) analogue combined with insulin reduces HbA1c and weight with low risk of hypoglycemia and high treatment satisfactionMarcus Lind, Johan Jendle, Ole Torffvit, et al.
Pageof 16